



20 April 2020

ASX ANNOUNCEMENT

Independent BIS RE-AIM Analysis to be Released at ASCO 2020

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced that new results from a Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) analysis of its BIS technology and lymphoedema prevention model-of-care were accepted as an abstract at the annual scientific meeting of the American Society of Clinical Oncology (ASCO), which will be conducted as a virtual meeting from 29 May to 2 June 2020.

Australian data from the interim analysis of the PREVENT trial were evaluated using the RE-AIM framework for the effectiveness of BIS technology and the early intervention model-of-care in preventing lymphoedema in public and private hospital settings. Lead abstract author was Deonni P. Stollendorf, PhD, and senior author was Sheila Ridner, PhD, both of Vanderbilt University School of Nursing. Other authors were Louise Koelmeyer (Macquarie University), John Boyages (Macquarie University and Icon Cancer Centre), Jerrod Nelms TTI Health Research and Economics, and Katrina Gaitatzis (Macquarie University).

“The interim analysis from the PREVENT trial already demonstrated that chronic lymphoedema can be preventable for patients with breast cancer,” said Professor John Boyages AM, founding director of the ALERT lymphoedema program and breast cancer radiation oncologist at Icon Cancer Center and co-author. “This analysis evaluated implementing a lymphoedema screening and early intervention program in both the public and private health care sectors. For too long, we have waited for patients to develop obvious arm swelling and then send them to a therapist usually when the changes were irreversible. It is important for clinicians to be confident that they can achieve positive outcomes for patients by implementing a lymphoedema prevention program using BIS at their institution, regardless of whether they are in the public or private setting. The exciting news is we can now detect lymphoedema when the arm still looks normal and introduce therapy perhaps up to 12 months earlier than can be detected by clinical examination.”

The RE-AIM framework is designed to assess the sustainability of evidence-based interventions and confirm that they can be implemented effectively across a broad range of care settings. The lymphoedema prevention model-of-care was studied in the PREVENT trial. An interim analysis from PREVENT showed that routine monitoring with L-Dex® combined with at-home intervention resulted in a 95% reduction in lymphoedema progression at one year. Today, L-Dex® is the only reliable, validated tool to detect subclinical lymphoedema. The company’s SOZO® digital health platform can measure a patient’s L-Dex score with a simple, painless 30-second test.

“This study will add to the growing body of evidence supporting the use of SOZO in an early intervention model of care,” said Richard Carreon, Managing Director and CEO of ImpediMed said “ASCO is the premier U.S. scientific conference for oncology, which lends a tremendous amount of credibility to this data.”

The American Society of Clinical Oncology (ASCO) and the Association for Clinical Oncology is a diverse network of nearly 45,000 oncology professionals. ASCO’s annual

scientific meeting is the largest annual gathering of the worldwide oncology community, in 2019 ASCO had more than 38,000 in attendance. This year due to COVID-19 the meeting will be conducted in a virtual format. More than 6,300 abstracts were received and reviewed by the Scientific Program Committee and ASCO Leadership. The abstract will be released by ASCO on 13 May 2020, at 5:00 PM EDT on abstracts.asco.org.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Richard Carreon
Managing Director & CEO

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.